euro adhoc: Sygnis Pharma AG / Fusion/Übernahme/Beteiligung / SYGNIS announces agreement on acquisition of Amnestix Inc., USA by partially using the authorized capital

--------------------------------------------------------------------------------
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer
europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.
--------------------------------------------------------------------------------

Unternehmen

08.06.2008

Heidelberg, June 8, 2008 - Today, after approval of the supervisory
board, SYGNIS Pharma AG signed a contract according to which SYGNIS
Pharma AG shall acquire all shares of Amnestix Inc., a
privately-owned US biopharmaceutical company located at Burlingame,
CA. With the acquisition of Amnestix Inc., SYGNIS extends its
portfolio of compounds relating to the central nervous system (CNS)
and secures IP-rights of compound-candidates for the treatment of
CNS-disorders. In addition, SYGNIS gains access to a broad range of
CNS projects within the Translational Genomics Research Institute in
Phoenix, Arizona, a world-renowned research-institute in the field of
neurogenomics. Amnestix was founded by scientists from Translational
Genomics Research Institute in 2006 to develop novel therapeutics and
molecular diagnostics technologies for improving cognition and
memory. The founders of Amnestix Inc. have discovered a series of
novel patentable genes and pathways that play a fundamental role in
memory performance in humans. Amnestix´ Chief Executive Officer, Dr.
Karoly Nikolich, will remain with Amnestix Inc. in this function.
SYGNIS will pay approximately EUR4 million in cash and in
SYGNIS-shares for all shares of Amnestix Inc. Therefore, the
management and supervisory board of SYGNIS Pharma AG resolved today
to issue 885.966 new common bearer SYGNIS-shares to the shareholders
of Amnestix Inc. for the contribution in kind with the exclusion of
the preemptive rights of SYGNIS shareholders. The current company´s
capital stock will be increased by approximately 3,2%.

For further information please contact:

Dr. Franz-Werner Haas
VP Operations / General Counsel
Tel: +49 (0) 6221-454 812
Email: franz-werner.haas@sygnis.de

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Rückfragehinweis:

Dr. Franz-Werner Haas

VP Operations / General Counsel

Tel: +49 (0) 179 212 33 95

Email: franz-werner.haas@sygnis.de

Branche: Biotechnologie
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Börse Frankfurt / Regulierter Markt/Prime Standard
Börse Berlin / Freiverkehr
Börse Hamburg / Freiverkehr
Börse Stuttgart / Freiverkehr
Börse Düsseldorf / Freiverkehr
Börse Hannover / Freiverkehr
Börse München / Freiverkehr